臨床婦人科産科69巻1号

2015年01月発行

今月の臨床 ゲノム時代の婦人科がん診療を展望する─がんの個性に応じたpersonalizationへの道

【各論3】卵巣がん

3．low-grade漿液性腺癌の臨床病理・ゲノムと治療法

著者： 本原剛志¹ 坂口勲¹ 片渕秀隆¹

所属機関： ¹熊本大学大学院生命科学研究部産科婦人科学

ページ範囲：P.118 - P.123

文献概要

●2004年にMD Andersonの研究グループは，卵巣漿液性腺癌をlow-gradeとhigh-gradeに分ける2段階の悪性度分類に基づく病理組織学的診断基準を提唱した．

●既存の抗がん剤に対して抵抗性を示すlow-grade漿液性腺癌では，MAPKシグナル経路の一連の活性化がみられており，これらのシグナル経路を標的としたMEK阻害薬の有効性が明らかにされた．

●卵巣がんに対する分子生物学的特性を基盤とした病態解明は，新規分子標的薬というツールを通じて，将来的な個別化治療へと展開されることが期待される．

参考文献

1） Shih Ie-M, et al : Ovarian tumorigenesis : a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164 : 1511─1518, 2004

2） Vang R, et al : Ovarian low-grade and high-grade serous carcinoma : pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16 : 267─282, 2009

3） Yap TA, et al : Beyond chemotherapy : targeted therapies in ovarian cancer. Nat Rev Cancer 9 : 167─181, 2009

4） Malpica A, et al : Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28 : 496─504, 2004

5） Romero I, et al : Low-grade serous carcinoma : new concepts and emerging therapies. Gynecol Oncol 130 : 660─666, 2013

6） Bodurka DC, et al : Reclassification of serous ovarian carcinoma by a 2-tier system : a Gynecologic Oncology Group Study. Cancer 118 : 3087─3094, 2012

7） Powell DE, et al : Current concepts in epithelial ovarian tumors : does benign to malignant transformation occur? Hum Pathol 23 : 846─847, 1992

8） Kurman RJ, et al : The origin and pathogenesis of epithelial ovarian cancer : a proposed unifying theory. Am J Surg Pathol 34 : 433─443, 2010

9） Jones S, et al : Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol 226 : 413─420, 2012

10） Singer G, et al : Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95 : 484─486, 2003

11） May T, et al : Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. Gynecol Oncol 117 : 9─17, 2010

12） Rajagopalan H, et al : Tumorigenesis : RAF/RAS oncogenes and mismatch-repair status. Nature 418 : 934, 2002

13） Cancer Genome Atlas Research Network : Integrated genomic analyses of ovarian carcinoma. Nature 474 : 609─615, 2011

14） Singer G, Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis : a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29 : 218─224, 2005

15） Gershenson DM, et al : Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 114 : 48─52, 2009

16） Seidman JD, et al : Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum. Gynecol Oncol 103 : 703─708, 2006

17） Motohara T, et al : Long-term oncological outcomes of ovarian serous carcinomas with psammoma bodies : a novel insight into the molecular pathogenesis of ovarian epithelial carcinoma. Cancer Sci 101 : 1550─1556, 2010

18） Gershenson DM, et al : Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108 : 361─368, 2006

19） Schmeler KM, et al : Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 108 : 510─514, 2008

20） Avruch J : MAP kinase pathways : the first twenty years. Biochim Biophys Acta 1773 : 1150─1160, 2007

21） Miller CR, et al : MEK1/2 inhibitors in the treatment of gynecologic malignancies. Gynecol Oncol 133 : 128─137, 2014

22） Flaherty KT, et al : Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367 : 1694─1703, 2012

23） Infante JR, et al : A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase（MEK） inhibitor, in combination with gemcitabine in advanced solid tumours. Eur J Cancer 49 : 2077─2085, 2013

24） Farley J, et al : Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum : an open-label, single-arm, phase 2 study. Lancet Oncol 14 : 134─140, 2013

25） Mahner S, et al : Towards individualised treatment in ovarian cancer. Lancet Oncol 14 : 101─102, 2013

26） Eisenstein M : Personalized medicine : Special treatment. Nature 513 : S8─9, 2014